Preserving the Status Quo: Keys to Maintaining a Healthy Ocu -

Name: Preserving the Status Quo: Keys to Maintaining a Healthy Ocular Surface
Uploaded: 2022-12-09T05:00:00+00:00
Duration: 1 h 26 min 42 s
Description: Ocular surface disease (OSD) is a multifactorial and complex disease that can negatively influence patient quality of life and the efficacy of ocular inter

Media formats available:

Details

Presenters

Overview
Ocular surface disease (OSD) is a multifactorial and complex disease that can negatively influence patient quality of life and the efficacy of ocular interventions.
Drs. Nichols and O'Dell have an engaging discussion that focuses on treatment for patients experiencing ocular discomfort from improper contact lens use; the importance of ocular surface health in pre- and postoperative dry eye management; the differences in artificial tear formulations that can impact OSD treatment; and best practices for in-office management of meibomian gland dysfunction.

This activity is supported by unrestricted educational grants from Alcon, Bausch + Lomb, and Sun Pharmaceutical Industries.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Evaluate the pathophysiology, risk factors, symptoms, and impact on patient quality of life of diseases that affect the ocular surface, namely dry eye disease (DED) and meibomian gland dysfunction (MGD)
- Review the role of a healthy ocular surface on contact lens wear
- Modify treatment plans for patients experiencing ocular discomfort from improper contact lens use
- Explain the importance of ocular surface health in pre- and postoperative dry eye management
- Discuss how differences in artificial tear formulations can impact the treatment of patients with DED and MGD
- Summarize best practices for the in-office management of MGD
Accreditation
Sponsored by
Evolve Medical Education, LLC is a COPE-Accredited Administrator.
This activity, COPE Activity Number 125184, is accredited by COPE for continuing education for optometrists. This course is approved for 1.5 hours of CE.
Course #: 82027-TD
Activity #: 125184
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Kelly K. Nichols, OD, MPH, PhD, FAAO
Professor and Dean
University of Alabama at Birmingham
School of Optometry
Birmingham, AL

Leslie O’Dell, OD, FAAO
Medical Director
Director of Clinical Research
Medical Optometry America
York, PA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alderya, Allergan/AbbVie, Axim, Bausch + Lomb, Bruder Healthcare, Dompé, HanAll Bio, Kala Pharmaceuticals, Novartis, Osmotica/RVL, Oyster Point Pharma, Palatin, Sight Sciences, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, Tear Film Innovations/Alcon, TearSolutions, Thea, TopiVert, Versea Visionology, Xequel, and YuYu Pharma. Grant/Research: Allergan/AbbVie, Aramis, Kala Pharmaceuticals, Kowa, ScienceBased Health, Sylentis, and Tear Science. Stock/Shareholder: Visionology.
Leslie O’Dell, OD, FAAO, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Alderya, Allergan, Bausch + Lomb, EyeDetech, Eye Eco, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocuphire, Oyster Point, Sight Sciences, Sun Pharmaceutical Industries, and Tarsus Pharmaceuticals. Speaker's Bureau: Aerie Pharmaceuticals, Alcon, Allergan/AbbVie, Bausch + Lomb, Kala Pharmaceuticals, Oyster Point Pharma, and Sun Pharmaceutical Industries. Stock/Shareholder: Eyes are the Story, EyeDetech, and Medical Optometry America.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Bausch + Lomb, or Sun Pharmaceutical Industries.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/09/2022
Expiration Date: 12/31/2023

Kelly K. Nichols, OD, MPH, PhD, FAAO

Guest

Leslie O’Dell, OD, FAAO

Guest

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
MinuteCE®
The Missed Diagnosis: A 45-Year-Old Software Engineer Who Complains of Dry Eyes
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
MinuteCE®
The Neverending Journey: A 66-Year-Old Patient Who Has Undergone Several Rounds of Tea Tree Oil–Based Treatment
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
Key Takeaways and Practice Integration
Key Takeaways and Practice Integration
MinuteCE®
Key Takeaways and Practice Integration
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
MinuteCE®
Return and Revisit: A 38-Year-Old Patient Returns for Follow-up After Lotilaner Treatment
Douglas K. Devries, OD; Cecelia Koetting, OD, FAAO
1.00 program credit
- Douglas K. Devries, OD
- Cecelia Koetting, OD, FAAO
1.00 program credit

Preserving the Status Quo: Keys to Maintaining a Healthy Ocular Surface

Recommended

Title